Study of bone marrow stem cells in multiple sclerosis

Sep 26, 2007

A new pilot clinical trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis has started at Frenchay Hospital. The aim of the trial, conducted by the University of Bristol and North Bristol NHS Trust, is to find out what effects, good or bad, it has on patients with MS, and their disability.

Bone marrow is known to contain stem cells capable of replacing cells in many types of tissues and organs - and so is of great interest to those working to develop new treatments for many diseases, including those affecting the nervous system.

The potential of such cells to aid repair in multiple sclerosis has been examined in laboratory studies in Bristol and elsewhere but, until now, patients have not been treated in this way.

Neil Scolding, Professor of Clinical Neurosciences for North Bristol NHS Trust and the University of Bristol is leading the trial.

He said: “We believe this form of adult stem cell treatment, carried out in collaboration with colleagues in the Bone Marrow Transplant Unit at the BRI, will be safe and well-tolerated but, because patients with MS have never had this treatment before, safety has to be proven before any further studies of larger numbers of patients can take place.

“We will therefore be monitoring this small number of patients extremely carefully over the next 9-12 months. Provided, as is envisaged, we do not find serious adverse effects, we hope to raise the funds to undertake a larger study to examine the effectiveness of such treatment in MS.”

What does this study involve?

Patients meeting the entry criteria were assessed in the Neurology department and the Burden Centre at Frenchay Hospital to determine general fitness and degree of disability from MS.

They also have various types of brain scan, at Frenchay and also at The Hammersmith Hospital in London. Then, at the Bone Marrow Transplant Unit at the BRI, they undergo bone marrow collection under a short general anaesthetic.

The marrow is processed and then delivered back to the patient later the same day via a vein in the arm.

Over the following weeks and months, a range of various monitoring tests and scans at Frenchay and in London are then carried out.

Source: University of Bristol

Explore further: First successful vaccination against 'mad cow'-like wasting disease in deer

add to favorites email to friend print save as pdf

Related Stories

Bristol-Myers pitches its cancer medicine pipeline

Jun 06, 2011

(AP) -- Bristol-Myers Squibb Co. executives said Monday they have more than a half-dozen drugs in testing against different cancers and could get important data on them and possibly a couple of approvals this year.

Cancer wins may be bigger than they seem

Jun 09, 2010

(AP) -- Doctors reported gains against nearly every form of cancer at a conference that ended this week. Yet when Will Thomas heard about an advance against prostate cancer, he wanted to know just one thing: "Is it a cure?"

Bone-marrow stem cells in MS show promise

May 05, 2010

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

Adult stem cell breakthrough

Nov 19, 2008

(PhysOrg.com) -- The first tissue-engineered trachea (windpipe), utilising the patient's own stem cells, has been successfully transplanted into a young woman with a failing airway. The bioengineered trachea ...

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.